Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells
Source abstract
Abstract
Fullerenes (C60) represent important carbon nanoparticles, widely investigated for diagnostic and therapeutic uses, mainly because they are characterized by a small size (between 7 and 10A ° ) and a large surface area. The cytotoxicity of two fullerene derivatives, functionalized by 1,3-dipolar cycloaddition of azomethine ylides to the C60 cage (1 and 2), the mechanism of cellular uptake (studied with a fluorescein-bearing derivative of 1, hereafter called derivative 3), and the intracellular distribution are the subject of this work.Cell cytotoxicity on human mammary carcinoma cell line (MCF7), evaluated with the MTT test and further confirmed by a flow cytometry approach with DiOC6 and PI probes, showed that derivative 1 was free of necrotic or apoptotic effects even after a long lasting cell exposure. Cell uptake and internalization of derivative 3 reach their zenith within 12 h after treatment, with a tendency to persist up to 72 h; this process was evaluated by flow cytometry and confirmed by confocal microscopy. Thus, it appears that a compound such as derivative 1 may be unspecifically taken up by MCF7 cells, in which it distributes throughout the cytoplasm, apparently avoiding any co-localization within the nucleus and secretory granules. These results suggest a strong interaction between the tested fullerene and mammalian cells and a significant ability of this compound to enter tumor cells, therefore resulting to be a suitable vector to deliver anticancer agents to tumor cells.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Fullerene Chemistry and Applications · Graphene and Nanomaterials Applications · Carbon Nanotubes in Composites
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–39810.1146/annurev.pharmtox.39.1.361 ↗
2. Bosi S, Da Ros T, Spalluto G, Prato M (2003) Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem 38(11–12):913–92310.1016/j.ejmech.2003.09.005 ↗
3. Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S (2009a) Shape effect of carbon nanovectors on angiogenesis. ACS Nano 4(1):574–58210.1021/nn901465h ↗
4. Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S (2009b) Fullerenol cytotoxic conjugates for cancer chemotherapy. ACS Nano 3(9):2505–251410.1021/nn900318y ↗
5. Debbage P (2009) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15(2):153–17210.2174/138161209787002870 ↗
6. Dellinger A et al (2010) Uptake and distribution of fullerenes in human mast cells. Nanomedicine 6:575–58110.1016/j.nano.2010.01.008 ↗
7. Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 14 57(15):2215–223710.1016/j.addr.2005.09.019 ↗
8. Duvvuri M, Krise JP (2005) Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci 10:1499–150910.2741/1634 ↗
9. Foley S, Crowley C, Smaihi M, Bonfils C, Erlanger BF, Seta P, Larroque C (2002) Cellular localization of a water-soluble fullerene derivative. Biochem Biophys Res Commun 294(1):116–11910.1016/S0006-291X(02)00445-X ↗
10. Gorczyca W (1999) Cytometric analyses to distinguish death processes. Endocr Relat Cancer 6:17–1910.1677/erc.0.0060017 ↗
11. Gotink K, Broxterman HJ, Labots M, De Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17(23):7337–734610.1158/1078-0432.CCR-11-1667 ↗
12. Guldi DM, Maggini M, Scorrano G, Prato M (1997) Intramolecular electron transfer in fullerene/ferrocene based donor-bridge-acceptor dyads. J Am Chem Soc 119:974–98010.1021/ja960070z ↗
13. Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812–81810.1016/j.drudis.2006.07.005 ↗
14. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86(4):368–37710.1038/clpt.2009.138 ↗
15. Kessel D, Wilberding C (1984) Mode of action of calcium antagonists which alter anthracycline resistance. Biochem Pharmacol 33(7):1157–116010.1016/0006-2952(84)90533-1 ↗
16. Kordatos K, Da Ros T, Bosi S, Vazquez E, Bergamin M, Cusan C, Pellarini F, Tomberli V, Baiti B, Pantarotto D, Georgakilas V, Spalluto G, Prato M (2001) Novel versatile fullerene synthons. J Org Chem 66:4915–492010.1021/jo015608k ↗
17. Kordatos K, Da Ros T, Prato M, Bensasson VR, Leach S (2003) Absorption spectra of monoaduct and eight bisadduct regioisomers of pyrrolidine derivatives of C60. Chem Phys 293:263–28010.1016/S0301-0104(03)00332-X ↗
18. Kurtoglu YE, Navath RS, Wang B, Kannan S, Romero R, Kannan RM (2009) Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials 30:2112–212110.1016/j.biomaterials.2008.12.054 ↗
19. Levi N, Hantgan RR, Lively MO, Carroll DL, Prasad GL (2006) C60-fullerenes: detection of intracellular photoluminescence and lack of cytotoxic effects. J Nanobiotechnol 4(4):1410.1186/1477-3155-4-14 ↗
20. Lu F, Haque ASK, Yang ST, Luo PG, Gu L, Kitaygorodskiy A, Li H, Lacher S, Sun YP (2009) Aqueous compatible fullerene–doxorubicin conjugates. J Phys Chem 113:17768–17773
21. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–28410.1016/S0168-3659(99)00248-5 ↗
22. Maggini M, Prato M (1998) Fulleropyrrolidines: a family of full-fledged fullerene derivatives. Acc Chem Res 31(9):519–52610.1021/ar970210p ↗
23. Maggini M, Scorrano G, Prato M (1993) Addition of azomethine ylides to C60: synthesis, characterization and functionalization of fullerene-pyrrolidines. J Am Chem Soc 115:9798–979910.1021/ja00074a056 ↗
24. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392
25. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19:311–33010.1096/fj.04-2747rev ↗
26. Monteiro-Riviere NA, Inman AO, Zhang LW (2009) Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol 234:222–23510.1016/j.taap.2008.09.030 ↗
27. Partha R, Conyers JL (2009) Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomed 4:261–27510.2217/nnm.09.11 ↗
28. Partha R, Mitchell LR, Lyon J, Joshi PP, Conyers JL (2008) Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery. ACS Nano 2(9):1950–195810.1021/nn800422k ↗
29. Surendiran A, Sandhiya S, Pradhan SC, Adithan C (2009) Novel application of nanotechnology in medicine. Indian J Med Res 130:689–701
30. Tattersall M, Clarke S (2003) Developments in drug delivery: implications for cancer care. Curr Opin Oncol 15:293–29910.1097/00001622-200307000-00003 ↗
31. Vail SA, Krawczuk PJ, Guldi DM, Palkar A, Echegoyen L, Tomé JPC, Fazio MA, Schuster DI (2005) Energy and electron transfer in polyacetylene-linked zinc-porphyrin-[60]fullerene molecular wires. Chem Eur J 11:3375–338810.1002/chem.200401348 ↗
32. Worle-Knirsch JM, Pulskamp K, Krug HF (2006) Oops they did it again! carbon nanotubes hoax scientists in viability assays. Nano Lett 6:1261–126810.1021/nl060177c ↗
33. Zhanga LW, Yang J, Barron AR, Monteiro-Riviere NA (2009) Endocytic mechanisms and toxicity of a fullerene in human cells. Toxicol Lett 191:149–15710.1016/j.toxlet.2009.08.017 ↗